Clinical development programmes in kidney diseases present unique pharmacovigilance challenges. Changes in renal function, disease related complications, and extensive laboratory monitoring often make the assessment of safety events particularly complex. Ensuring accurate safety evaluation requires a combination of medical expertise, robust safety processes, and continuous regulatory oversight.
This case study highlights how AWINSA Life Sciences provided end to end pharmacovigilance support for a global Phase 3 clinical programme in Primary Membranous Nephropathy (PMN). Through integrated safety monitoring, medical review, signal detection, regulatory compliance management, and safety data reconciliation, AWINSA helped the sponsor maintain patient safety, data integrity, and regulatory compliance throughout the clinical development lifecycle.
Copyright © 2024 AWINSA Life Sciences Pvt. Ltd. All rights reserved.
59 E,Shrewsbury Place
Princeton, NJ 08540
United States
E13/9 First floor, Vasant Vihar,
New Delhi 110057
Wilhelmina Druckerlaan 10,
6532 SR,
Nijmegen,
The Netherlands
Cerrada Ahuizotla 53,
Col. Santiago Ahuizotla,
Del. Azcapotzalco
CP.02750
Ciudad de México, México.
